AMLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Amylyx Pharmaceuticals Inc (AMLX) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financial performance is weak, with significant declines in revenue, net income, and EPS. Insider selling has surged, and there are no recent positive news catalysts. While analysts maintain a Buy rating, the stock's technical indicators and lack of proprietary trading signals suggest no immediate entry point. A hold is recommended until clearer positive catalysts or stronger financial performance emerge.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 45.828, and moving averages are converging, showing no clear trend. The stock is trading below the pivot point of 14.218, with key support at 13.228 and resistance at 15.207.
Analyst Andrew Fein raised the price target to $28, citing a de-risked path to approval for the LUCIDITY trial. The company has a cash runway until 2028, providing financial stability.
Insider selling has increased significantly by 4098.14% over the last month. The company's financial performance has deteriorated sharply, with revenue, net income, and EPS all declining significantly YoY. No recent news or Congress trading data is available to support a positive outlook.
In Q3 2025, revenue dropped to $0 (-100% YoY), net income fell to -$34.39M (-52.7% YoY), EPS decreased to -0.37 (-65.42% YoY), and gross margin dropped to 0 (-100% YoY).
Analysts maintain a Buy rating. H.C. Wainwright raised the price target to $28, citing a de-risked trial design for LUCIDITY. However, BofA lowered the price target to $15, citing weak Q3 earnings but highlighting the cash runway to 2028.
